Spyre Therapeutics(SYRE) - 2023 Q1 - Quarterly Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 AEGLEA BIOTHERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 46-4312787 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 805 Las Cimas Parkway Suite 100 Austin, TX 78746 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT ...